Welcome to our dedicated page for Alps Group SEC filings (Ticker: ALPS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alps Group Inc filings document the company's foreign private issuer current-report disclosures following its completed SPAC business combination and public-company transition. Form 6-K reports furnish material-event updates, press releases, governance changes, board appointments, committee service, executive leadership appointments, employment agreement terms, capital-structure matters, and security-structure disclosures.
The filing record also covers company-specific biotechnology disclosures, including peer-reviewed case reports involving autologous Natural Killer cell infusions produced with an in-house culture protocol and CELESOME(+) exosome-related development activities. These documents frame Alps Group's formal disclosures around clinical-program communications, corporate governance, material agreements, and operating and financial reporting categories.
Alps Group Inc reported that its board appointed Cheing Lye-Ping (Penny) as Chief Financial Officer, effective January 5, 2026. She will lead financial strategy, budgeting, planning and analysis, audit, tax compliance, risk management, accounting, and treasury for the company and its subsidiaries.
Ms. Cheing brings over 30 years of finance and accounting experience, including prior roles as CFO and CEO in Malaysian property and investment businesses, as well as earlier work at Arthur Andersen across multiple industries. Under a one-year executive employment agreement, she will receive an annual base salary of $59,000, with standard benefits and negotiated severance if terminated without cause or for Just Cause as defined in the agreement. The company states there are no family relationships or special arrangements connected to her appointment.